美国国立癌症研究所匹配试验推动癌症综合试验模式。 - Suppr

Suppr

超能文献

NCI-MATCH trial pushes cancer umbrella trial paradigm.

作者信息

Mullard Asher

出版信息

Nat Rev Drug Discov. 2015 Aug;14(8):513-5. doi: 10.1038/nrd4694.

DOI:10.1038/nrd4694

PMID:26228747

Abstract

摘要

相似文献

NCI-MATCH trial pushes cancer umbrella trial paradigm.

Nat Rev Drug Discov. 2015 Aug;14(8):513-5. doi: 10.1038/nrd4694.

NCI-MATCH launch highlights new trial design in precision-medicine era.

J Natl Cancer Inst. 2015 Jul 3;107(7). doi: 10.1093/jnci/djv193. Print 2015 Jul.

American Society of Clinical Oncology Developing First Clinical Trial.

J Natl Cancer Inst. 2015 Nov 4;107(11):djv356. doi: 10.1093/jnci/djv356. Print 2015 Nov.

An overview of the NCI precision medicine trials-NCI MATCH and MPACT.

Chin Clin Oncol. 2015 Sep;4(3):31. doi: 10.3978/j.issn.2304-3865.2015.08.01.

National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.

Am Soc Clin Oncol Educ Book. 2014:71-6. doi: 10.14694/EdBook_AM.2014.34.71.

Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.

Curr Probl Cancer. 2017 May-Jun;41(3):182-193. doi: 10.1016/j.currproblcancer.2017.02.001. Epub 2017 Feb 11.

More trials, fewer tribulations.

Sci Am. 2014 Jul;311(1):S9-11.

Identifying cancer mutations as therapeutic targets.

J Natl Cancer Inst. 2014 Aug 13;106(8). doi: 10.1093/jnci/dju276. Print 2014 Aug.

National Cancer Institute Basket/Umbrella Clinical Trials: MATCH, LungMAP, and Beyond.

Cancer J. 2019 Jul/Aug;25(4):272-281. doi: 10.1097/PPO.0000000000000389.

Is there room for improvement in adverse event reporting in the era of targeted therapies?

J Natl Cancer Inst. 2008 Feb 20;100(4):240-2. doi: 10.1093/jnci/djm324. Epub 2008 Feb 12.

引用本文的文献

Monoclonal antibody immune therapy response instrument for stratification and cost-effective personalized approaches in 3PM-guided pan cancer management.

EPMA J. 2025 Mar 22;16(2):465-503. doi: 10.1007/s13167-025-00403-w. eCollection 2025 Jun.

Phase II Study of Defactinib (VS6063) in Patients With Tumors With Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.

JCO Precis Oncol. 2024 Dec;8:e2400327. doi: 10.1200/PO.24.00327. Epub 2024 Dec 18.

New clinical trial design in precision medicine: discovery, development and direction.

Signal Transduct Target Ther. 2024 Mar 4;9(1):57. doi: 10.1038/s41392-024-01760-0.

Moving pan-cancer studies from basic research toward the clinic.

Nat Cancer. 2021 Sep;2(9):879-890. doi: 10.1038/s43018-021-00250-4. Epub 2021 Sep 16.

Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer.

J Cancer Sci Clin Ther. 2021 Mar 18;5(1):134-153. doi: 10.26502/jcsct.50790107.

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.

Nat Commun. 2021 Aug 24;12(1):5086. doi: 10.1038/s41467-021-25177-3.

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.

JAMA Oncol. 2021 Feb 1;7(2):271-278. doi: 10.1001/jamaoncol.2020.6741.

Comparing the Efficacy of Cancer Therapies between Subgroups in Basket Trials.

Cell Syst. 2020 Nov 18;11(5):449-460.e2. doi: 10.1016/j.cels.2020.09.003.

Molecular Profiling-Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges.

Front Oncol. 2020 Oct 27;10:532403. doi: 10.3389/fonc.2020.532403. eCollection 2020.

Precision Pharmacotherapy: Integrating Pharmacogenomics into Clinical Pharmacy Practice.

J Am Coll Clin Pharm. 2019 Jun;2(3):303-313. doi: 10.1002/jac5.1118. Epub 2019 Jun 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验